

GPTHEALTH/CS/SE/2023-24

March 19, 2024

The Department of Corporate Services BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street Mumbai - 400001 Scrip Code: 544131	National Stock Exchange of India Limited Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex, Bandra (E), Mumbai - 400 051 Scrip Symbol: GPTHEALTH
---	--

Dear Sir/Madam

Sub: Submission of Un-Audited Financial Results for the Quarter and Nine Months ended December 31, 2023

In pursuance of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform you that the Board of Directors at their meeting held today i.e. March 19, 2024, have interalia considered, approved and taken on record, the Un-Audited Financial Result along with Limited Review Report of the Statutory Auditors thereon of the Company for the Quarter & Nine Months ended December 31, 2023.

A copy of the Un-Audited Financial Result along with Limited Review Report of the Statutory Auditors thereon of the Company for the Quarter & Nine Months ended December 31, 2023, as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, is enclosed herewith for your record and reference.

Kindly take the aforesaid information on record and oblige.

Thanking You,

Yours sincerely,

For GPT Healthcare Limited

Ankur Sharma
Company Secretary and Compliance Officer
M. No A31833

Independent Auditor's Review Report on Unaudited Financial Results of GPT Healthcare Limited for the quarter and nine months ended December 31, 2023 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors
GPT Healthcare Limited

1. We have reviewed the accompanying statement of unaudited financial results ("the statement) of **GPT Healthcare Limited** ("the Company") for the quarter and nine months ended December 31, 2023. The statement is being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, ("The Regulation") and has been initialed by us for identification purpose.
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors in their meeting held on March 19, 2024, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133, of the Companies Act, 2013 as amended read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Attention is drawn to Note 2 of the Statement which states that the figures for the quarter ended September 30, 2023 and corresponding quarter and nine months ended December 31, 2022, as reported in the accompanying Statement have been approved by the Company's Board of Directors, but have not been subjected to review by the statutory auditor of the Company since the requirement of submission of the quarterly results is applicable on listing of the equity shares of the Company from the quarter ended December 31, 2023.

Further, the figures for the year ended March 2023 have been extracted from the audited standalone financial statement which were prepared in accordance with the requirements of Companies Act, 2013 and audited by us and on which we had issued our unmodified opinion vide our report dated June 20, 2023.

Our conclusion is not modified in respect of above matters.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard ('Ind AS') specified under section 133, of the Companies Act, 2013 as amended read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulation, including the manner in which it is to be disclosed, or that it contains any material misstatement.



For Singhi & Co.
Chartered Accountants
Firm Registration No. 302049E

NAVINDRA
KUMAR SURANA
Digitally signed by NAVINDRA
KUMAR SURANA
Date: 2024.03.19 15:22:46
+05'30'

(Navindra Kumar Surana)
Partner

Membership No. 053816
UDIN: 24053816BKACCA2212

Place: Kolkata
Date: March 19, 2024

GPT HEALTHCARE LIMITED

Registered Office: GPT Centre, JC-25, Sector - III, Salt Lake City, Kolkata - 700 106, India
CIN : U70101WB1989PLC047402, Website: www.ilshospitals.com, Email : ghl.cosec@gptgroup.co.in



STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS PERIOD ENDED DECEMBER 31, 2023

₹ in lakhs (except per share data)

Particulars	Quarter Ended			Nine months period ended		Year ended
	31-Dec-23 (Unaudited)	30-Sep-23 (Refer Note-2)	31-Dec-22 (Refer Note-2)	31-Dec-23 (Unaudited)	31-Dec-22 (Refer Note-2)	31-Mar-23 (Audited)
1 INCOME						
(a) Revenue from operations	9,659.17	10,797.51	9,298.72	30,076.73	26,495.41	36,103.71
(b) Other income	117.82	108.72	85.51	369.92	336.17	569.36
Total Income	9,776.99	10,906.23	9,384.23	30,446.65	26,831.58	36,673.07
2 Expenses						
(a) Cost of materials consumed	1,969.56	2,238.87	1,911.85	6,217.42	5,555.45	7,586.34
(b) Employee benefits expense	1,726.21	1,744.23	1,563.32	5,193.72	4,709.18	6,203.79
(c) Finance costs	169.05	181.44	228.49	551.10	664.29	916.39
(d) Depreciation and amortisation expense	450.11	438.54	394.62	1,322.32	1,087.17	1,491.23
(e) Other expenses	3,863.31	4,354.55	3,788.13	12,199.18	11,153.60	14,878.38
Total Expenses	8,178.24	8,957.63	7,886.41	25,483.74	23,169.69	31,076.13
3 Profit before Tax (1-2)	1,598.75	1,948.60	1,497.82	4,962.91	3,661.89	5,596.94
4 Tax expense						
a) Current tax	282.00	340.00	261.00	869.00	639.00	975.00
b) Deferred tax (including MAT Credit entitlement)	169.75	258.30	401.42	598.64	489.00	722.64
c) Income tax for earlier year	-	-	-	-	-	(1.46)
Total Tax expenses	451.75	598.30	662.42	1,467.64	1,128.00	1,696.18
5 Profit for the period (5-4)	1,147.00	1,350.30	835.40	3,495.27	2,533.89	3,900.76
6 Other Comprehensive Income						
<u>A. Items that will not be reclassified to profit or loss</u>						
a) Remeasurement of defined benefit plan	(10.00)	5.04	11.30	(40.27)	11.40	18.93
b) Income tax relating to above	2.92	(1.46)	(3.29)	11.74	(3.32)	(5.52)
<u>B. Items that will be reclassified to profit or loss</u>	-	-	-	-	-	-
Other Comprehensive Income for the period	(7.08)	3.58	8.01	(28.53)	8.08	13.41
7 Total Comprehensive Income for the period (5+6)	1,139.92	1,353.88	843.41	3,466.74	2,541.97	3,914.17
8 Paid up equity share capital (face value of ₹ 10 each)	799.04	799.04	799.04	799.04	799.04	799.04
9 Other Equity						854.58
11 Earnings per equity share (of Rs. 10 each) :						
(a) Basic (Rs.)	1.44 *	1.69 *	1.05 *	4.37 *	3.17 *	4.88
(b) Diluted (Rs.)	1.44 *	1.69 *	1.05 *	4.37 *	3.17 *	4.88
* Not annualized						

NAVINDRA
KUMAR
SURANA

Digitally signed by
NAVINDRA KUMAR
SURANA
Date: 2024.03.19
15:24:02 +05'30'

**DWARIKA
PRASAD
TANTIA** Digitally signed by
DWARIKA PRASAD
TANTIA
Date: 2024.03.19
15:16:31 +05'30'

Notes:

- 1 This statement have been prepared in accordance with the recognition and measurements principles as laid down in Indian Accounting Standard ("Ind AS") 34 - "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 2 The above unaudited financial results were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on March 19, 2024. The said results have subject to limited review by the statutory auditors of the company for the quarter and nine months December 31, 2023. The financial results for the quarter and nine months ended December 31, 2022 and for the quarter ended September 30, 2023 have not been reviewed / audited by the statutory auditors. The management has exercised necessary diligence to ensure that the financial results for the periods provide a true and fair view of the Company's affairs.
- 3 GPT Healthcare Limited ("the Company") has completed Initial Public Offering (IPO) comprising of fresh issue of 21,50,537 equity shares and offer for sale from investor selling shareholder of 2,60,82,786 equity shares of face value ₹10 each at an issue price of ₹186 per share for cash consideration aggregating to ₹525.14 Crores, subsequent to quarter ended December 31, 2023. Pursuant to IPO, equity shares of the Company were listed on BSE Limited and National Stock Exchange w.e.f. February 29, 2024. The above statement of unaudited financial results for the quarter and nine months ended December 31, 2023 are drawn up in accordance with the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.
- 4 The company operates in one single reportable business segment and geographical segment i.e. healthcare service in India.
- 5 The Board of Directors of the Company have declared a second Interim Dividend @ 10% i.e. ₹1 per Equity Share. The record date for payment of second interim dividend has been fixed as April 1, 2024. Total dividend for the financial year 2023-24 is ₹2 per Equity share on the face value of ₹10 per share.
- 6 The above unaudited financial results are also available on the Company's website www.ilshospitals.com and also on the stock exchange websites (www.bseindia.com and www.nseindia.com).

NAVINDRA
KUMAR
SURANA

Digitally signed by
NAVINDRA KUMAR
SURANA
Date: 2024.03.19
15:24:37 +05'30'

For and on behalf of the Board

DWARIKA
PRASAD TANTIA

Digitally signed by
DWARIKA PRASAD TANTIA
Date: 2024.03.19 15:16:55
+05'30'

Dwarika Prasad Tantia
Chairman and Whole Time Director
DIN: 00001341

Place : Kolkata

Date : March 19, 2024